



## CGM Sensor Insertion and Removal Instructions

### IMPORTANT:

- Only qualified healthcare providers who have successfully completed the Eversense E3 CGM Insertion and Removal Training Programme and have read and understood the Eversense E3 CGM Sensor Insertion and Removal Instructions may perform the insertion and removal procedure on patients. Contact Senseonics (in the US toll free at 844-SENSE4U (844-736-7348)) if training has yet to be conducted or if you experience any difficulty or issues with the insertion or removal procedure. Outside the US, call your local distributor or visit <https://global.eversensed diabetes.com> to locate your local distributor.
- All symptoms of infection (e.g., increased temperature, inflammation, redness, pain, tenderness, warmth, swelling or purulence) at the insertion or removal area should be reported. If any of the above occurs, please advise patients to contact their healthcare provider immediately.
- Store the sensor kit refrigerated at the labelled temperature range.



# I. Overview of the Eversense E3 Continuous Glucose Monitoring (CGM) System

---

Congratulations on having Eversense E3 CGM technology to assist your patients in managing their diabetes. The Eversense E3 CGM System is for people with diabetes to continually measure glucose levels for up to 180 days from the time of sensor insertion.

Some of the features of the Eversense E3 CGM System:

- Wireless communication with the sensor, smart transmitter and app.
- Long-term sensor wear in the upper arm for up to 180 days.
- Alerts when pre-set Low or High Glucose Alert levels (hypoglycaemia or hyperglycaemia) are passed.
- Predictive alerts to alert the patient before reaching pre-set Low or High Glucose Alert levels.
- Use of mobile device (e.g., smartphone) to display glucose readings.
- On-body vibe alerts with the smart transmitter even when mobile device is not nearby.
- Provides readings within 40-400 mg/dL (2.2-22.2 mmol/L) range every 5 minutes.
- Trend arrows that show whether glucose values are rising or falling and how fast.
- Graphs and statistics that show glucose results in easy-to-understand formats.
- Removable and rechargeable smart transmitter.
- Event entry capabilities (like meals, exercise and insulin).
- Stores glucose data in the app and on the smart transmitter.

## Eversense E3 CGM System Components

The System includes:

- 1) a small sensor inserted subcutaneously by a healthcare provider,
- 2) a removable smart transmitter worn over the sensor, and
- 3) a mobile app to display the glucose readings.

### Eversense E3 Sensor

The sensor is inserted under the skin (upper arm) and measures glucose in interstitial fluid for up to 180 days. These glucose levels are then calculated by the smart transmitter and sent to the app.

The Eversense E3 Sensor lasts up to 180 days. The sensor has a silicone ring that contains a small amount of dexamethasone acetate, an anti-inflammatory steroid drug. The dexamethasone acetate minimises inflammatory responses, very similar to common medical devices, such as pacemakers.


Specially designed sensor insertion tools are provided for subcutaneous insertion of the sensor. Other equipment necessary for the procedure, but not included in the Eversense E3 Insertion Tool Kit, is listed in *Section 4*.

### Eversense E3 Smart Transmitter

The removable smart transmitter is worn externally over the sensor and powers the sensor. It wirelessly sends glucose data (via Bluetooth) to the mobile app. The smart transmitter also provides on-body vibe alerts based on the pre-set glucose level settings. It has a rechargeable battery that is reusable for up to one year. Adhesive patches are shipped to the healthcare provider along with the Eversense E3 Sensor Kit, and are provided for the patient to replace daily.

### Eversense App

The Eversense App is a software application that runs on a mobile device (e.g., smartphone) and displays glucose data in a variety of ways. It also provides alerts based on the pre-set glucose level settings.



**Note:** Not actual size

## 2. Benefits and Risks

*This section describes the benefits, expectations and risks associated with using the Eversense E3 CGM System. Additional safety information is available at <https://ec.europa.eu/tools/eudamed> (European database on medical devices – EUDAMED) in the Eversense E3 CGM System Summary of Safety and Performance (SSCP), or upon request to Customer Support. The SSCP is linked to the Eversense E3 CGM system component Basic UDI-DI numbers that are listed on the back cover of this Instruction Manual.*

Continuous glucose monitoring aids in the management of diabetes and glucose control, which can improve your patient's quality of life. Best results are achieved when the user is fully informed about the risks and benefits, insertion procedure, follow-up requirements, and self-care responsibilities. Patients should not have the sensor inserted if they cannot properly operate the CGM System.

The CGM System measures glucose in interstitial fluid (ISF) between the body's cells. Physiologic differences between ISF and blood from a fingerstick may result in differences in glucose measurements. These differences are especially evident during times of rapid change in blood glucose (e.g., after eating, dosing insulin, or exercising), and for some people, during the first several days after insertion due to inflammation that may result from the insertion procedure. Glucose levels in ISF lag behind glucose levels in blood by several minutes.

**IMPORTANT:** If symptoms do not match the glucose alerts and readings from the Eversense E3 CGM System, a fingerstick blood glucose check with a home blood glucose meter should be performed prior to making treatment decisions.

Failure to use the Eversense E3 CGM System in accordance with the instructions for use may result in missing a hypoglycaemic or hyperglycaemic glucose event, which may result in injury. In the *Eversense E3 CGM System User Guide* provided in the smart transmitter kit box for patients, the section titled *Understanding Treatment Decisions with CGM* provides instructions for patients.

The sensor has a silicone ring that contains a small amount of an anti-inflammatory drug (dexamethasone acetate). It has not been determined whether the risks associated with injectable dexamethasone acetate apply to the dexamethasone acetate elution ring inside the sensor. The elution ring releases a small amount of dexamethasone acetate when the sensor comes in contact with body fluids and serves to minimise the body's inflammatory response to the inserted sensor. Dexamethasone acetate in the ring may also cause other adverse events not previously seen with the injectable form.

## Indications for Use

The Eversense E3 CGM System is indicated for continually measuring glucose levels in adults (18 years or older) with diabetes for up to 180 days. The system is indicated for use to replace fingerstick blood glucose measurements for diabetes treatment decisions.

The system is intended to:

- Provide real-time glucose readings.
- Provide glucose trend information.
- Provide alerts for the detection and prediction of episodes of low blood glucose (hypoglycaemia) and high blood glucose (hyperglycaemia).
- Aid in the management of diabetes.

Historical data from the system can be interpreted to aid in providing therapy adjustments. These adjustments should be based on patterns and trends seen over time. The system is intended for single patient use.

## MRI Safety Information

A patient with this device can be safely scanned in a horizontal, closed bore MR scanner meeting the following conditions:

- Static magnetic field of 1.5 T or 3.0 T.
- Maximum spatial field gradient of 1900 gauss/cm ( $\leq 19$  T/m).
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 4 W/kg (First Level Controlled Operating Mode) for 15 minutes of continuous scanning, or SAR of 2 W/kg for 30 minutes of continuous scanning.

Under the scan conditions defined above, non-clinical testing results indicate the Eversense E3 Sensor is expected to produce a maximum temperature rise of less than 5.4°C. In non-clinical testing, the image artifact caused by the device extends approximately 72 mm (2.83 inches) from the Eversense E3 Sensor when imaged with a gradient echo pulse sequence and a 3T MR system.

The Eversense E3 Sensor has not been tested in MR systems that do not meet the conditions above. Exposing the Eversense E3 Sensor to MRI conditions which are outside of the conditions outlined above can cause potential complications such as device migration, heating and tissue damage or erosion through the skin.

The Eversense E3 Smart Transmitter is MR Unsafe and MUST BE REMOVED before undergoing an MRI procedure. Before you undergo an MRI procedure, tell the MRI staff that you have an Eversense E3 Sensor and Smart Transmitter, and consult with the healthcare provider who inserted your sensor.

For the most updated version of the Eversense E3 CGM System labelling, visit <https://global.eversensed diabetes.com>. You will receive an International Implant Card from your healthcare provider with each sensor insertion. Keep this card in your wallet as a reference.

## Contraindications

The system is contraindicated in people for whom dexamethasone or dexamethasone acetate may be contraindicated.

The smart transmitter is incompatible with magnetic resonance imaging (MRI) procedures. Patients should not undergo an MRI procedure when wearing the smart transmitter. For information on the sensor, please see *MRI Safety Information*.

Mannitol or sorbitol, when administered intravenously, or as a component of an irrigation solution or peritoneal dialysis solution, may increase blood mannitol or sorbitol concentrations and cause falsely elevated readings of your sensor glucose results. Sorbitol is used in some artificial sweeteners, and concentration levels from typical dietary intake do not impact sensor glucose results.

## Risks and Side Effects

The glucose alerts and notifications will not audibly notify the user when the sound on their mobile device is turned off. If the system cannot display a glucose value, it also cannot provide glucose alerts. If the patient is unable to feel the vibration of the smart transmitter they may not notice the alerts. Medical attention may be needed in the event that they have high or low glucose and are unaware of it.

**IMPORTANT:** If the patient does not check their glucose with a blood glucose meter when symptoms are not consistent with the sensor glucose readings, they may miss a high or low glucose event.

Treatment decisions should be made based on a review of the following: a sensor glucose value, trend arrow, recent glucose trend graph, and system alerts/notifications. Patients should not make treatment decisions unless they have considered all of this information. Patients should understand insulin action, and factor in its impact on glucose prior to making a treatment decision.

The sensor is inserted by making a small incision and placing it under the skin. This process may cause infection, pain or skin irritation. Additionally, the adhesive may cause a reaction or skin irritation. Dizziness, fainting and nausea were reported in small numbers during clinical studies, as were instances of the sensor breaking or not being removed on first attempt. Any medical issue related to the procedure or use of the device should be reported to the patient's health-care provider. The sensor will require an additional removal procedure at the end of sensor life.

## Warnings

- The Eversense E3 CGM System has not been tested using insertion sites other than the upper arm.
- Before making treatment decisions, patients should take into account the sensor glucose value, the trend graph, the trend arrow and any alerts from the Eversense E3 CGM System. If no trend arrow is displayed, the system does not have enough data to display direction and rate of change. Treatment decisions should not be based solely on the sensor glucose value.
- If at any time a patient's symptoms are not consistent with the sensor glucose readings, patients should test glucose levels with a blood glucose meter.
- Patients should not use a smart transmitter if it is damaged or cracked as this could result in electrical shock.
- Patients should avoid close contact with electromagnetic interference (EMI) while wearing the smart transmitter.
- Antibiotics of the tetracycline class may falsely lower sensor glucose readings. Patients should not rely on sensor glucose readings while taking tetracyclines.
- The bandage should remain covering the incision for 48 hours as this is a standard of care to allow formation of a water-tight seal to help protect against infection. Until it has healed, patients should always cover the insertion site with a sterile bandage before placing the smart transmitter adhesive over the sensor. Failure to do so could result in infection at the insertion site.
- The system should only be calibrated using a fingerstick blood sample. Alternative sites (such as forearm or palm) should not be used to calibrate the system.
- Insulin should not be injected and infusion sets for insulin pumps should not be inserted within 4 in (10.16 cm) of the sensor site. If the insulin delivery site is within 4 in (10.16 cm) of the sensor site, it may interfere with sensor glucose readings and can cause inaccurate glucose readings.



## Warnings (continued)

- Patient should always follow their healthcare provider's instructions for care after the sensor insertion or removal. Patients should contact their healthcare provider if any of the following events occur:
  - Pain, redness, or swelling at the incision site(s) later than 5 days after the sensor insertion or removal, or if the incision has not healed within 5 to 7 days.
- If sensor glucose is very low (below 40 mg/dL or 2.2 mmol/L) or very high (above 400 mg/dL or 22.2 mmol/L), the patient should perform a fingerstick blood glucose test prior to making a treatment decision.
- The Eversense E3 CGM System requires calibration in order to provide accurate readings. The patient should not use CGM readings to make treatment decisions unless they have followed the instructions for daily calibration.
- The Eversense E3 CGM System will not provide readings during the 24-hour Warm-Up Phase and until a second calibration is successful during the Initialisation Phase. During this time, the patient should monitor their glucose using a home blood glucose monitor.
- Certain conditions and alerts will prevent glucose data from being displayed. During these times, the patient should use a home blood glucose monitor to make treatment decisions. The patient should carefully read the *Alerts and Notifications* section of their *Eversense E3 CGM System User Guide* to understand these conditions.
- The glucose alerts and notifications will not audibly notify the patient when the sound on the mobile device is turned off. If the system cannot display a glucose value, it also cannot provide glucose alerts. If the patient is unable to feel the vibration of the smart transmitter they may not notice the alerts.
- When the smart transmitter is not worn over the sensor, such as during charging, the Eversense E3 CGM System will not provide alerts and notifications on the mobile device or via vibration alerts from the smart transmitter.

## Cautions

- The sensor and sensor holder are sterile in the unopened, undamaged, sterile package. The sensor should not be used if the sterile package has been opened or damaged.
- A sensor should not be inserted if it has been dropped from a height greater than 30 cm.
- Use only the insertion tools provided in the insertion tools kit to insert the sensor. Other insertion tools may damage the sensor.
- Instruct patients to notify airport security personnel of the presence of the device when going through the security system.
- Patients should NOT exchange smart transmitters with another person. Each smart transmitter can be linked to only one sensor at a time. The system is to be used by a single patient in the home environment.
- The following medical therapies or procedures have not been tested with the Eversense E3 Sensor and may cause permanent damage to the sensor particularly if used in close proximity to the device:
  - **Lithotripsy** – The use of lithotripsy is not recommended for people who have an inserted sensor because the effects are unknown.
  - **Diathermy** – DO NOT use diathermy on people who have an inserted sensor. Energy from the diathermy can transfer through the sensor and cause tissue damage in the insertion area.
  - **Electrocautery** – The use of electrocautery near the inserted sensor may damage the device. DO NOT use electrocautery near the sensor.
- Patients should NOT wear the smart transmitter during medical x-rays or computed tomography (CT) scans. To avoid interference with results, the smart transmitter should be removed before undergoing medical x-ray or CT scans.
- The sensor and smart transmitter should be linked the day of insertion. Failure to link the sensor and smart transmitter could result in a delay in receiving glucose readings.
- **Steroid use** – It has not been determined whether the risks usually associated with injectable dexamethasone acetate apply to the use of this dexamethasone acetate elution ring, a highly localised, controlled-release device. The dexamethasone acetate ring could cause other adverse events not listed or previously seen.
- If the sensor, insertion site or smart transmitter feels warm, the patient should remove the smart transmitter immediately and contact his/her healthcare provider for further advice. A warm sensor could mean there is an infection or a sensor malfunction.

## Cautions (continued)

- Patients should NOT attempt to use the Eversense App while operating a motor vehicle.
- Patients should not receive massage therapy near the inserted sensor site. Massage therapy near the sensor site could cause discomfort or skin irritation.
- Patients should use only the AC power adapter and USB cable provided with the smart transmitter when charging the smart transmitter battery. Use of another power supply could damage the smart transmitter, not allowing glucose readings to be received properly, and could result in voiding the warranty.
- If the patient has any concerns about allergic reaction to adhesive products containing silicone, they should contact the healthcare provider prior to use. The Eversense adhesive patch should be discarded after each use of up to 24 hours.
- Patients should not change the unit of measurement unless they have discussed it with their healthcare provider. Using the incorrect unit of measure could result in missing a high or low glucose event.
- Entering incorrect blood glucose values for calibration can result in inaccurate sensor glucose readings, which may result in the user missing a high or low glucose event.
- Patients should follow their healthcare provider's recommendation for setting their glucose alerts. Incorrectly setting the glucose alerts can result in the user missing a high or low glucose event.
- Patients should pay attention to the glucose alerts the system provides. Failure to appropriately respond to an alert might result in the user missing a high or low glucose event.
- The Eversense NOW Remote Monitoring App does not replace the monitoring regimen as directed by the healthcare provider.
- The Eversense E3 CGM System has not been tested in the following populations: women who are pregnant or nursing, people under the age of 18, critically ill or hospitalised patients, people receiving immunosuppressant therapy, chemotherapy or anti-coagulant therapy, those with another active implantable device, e.g., an implantable defibrillator (passive implants are allowed, e.g., cardiac stents), those with known allergies to or using systemic glucocorticoids (excluding topical, optical or nasal, but including inhaled). The system's accuracy hasn't been tested in these populations, and sensor glucose readings may be inaccurate, resulting in missing a severe low or high glucose event.

# 3. Eversense E3 CGM System Candidates and Pre-Insertion Activities

## Candidate Selection

Per ACE/AACE guidelines\*, potential candidates for CGM include those patients:

- Taking insulin to treat their T1 or T2 diabetes, and motivated to optimise their blood glucose management with the addition of new glucose monitoring technology.
- Able to follow device labelling and use their blood glucose meter results to make treatment decisions under certain conditions.  
See *Understanding Treatment Decisions with CGM* in the *Eversense E3 User Guide*.
- Have hypoglycaemic unawareness/frequent hypoglycaemia.
- With their haemoglobin A1c (HbA1c) over target, or with excess glycaemic variability – requiring HbA1c lowering without increased hypoglycaemia.

## Eversense E3 CGM System Candidates

- Must have a compatible Android or IOS device, be familiar with its functionality and have internet connectivity. For a list of compatible devices, visit <https://global.eversensedidiabetes.com>.
- Willing to enter a calibration blood glucose (BG) into the app when prompted.
- Discuss appropriate placement of sensor insertion and smart transmitter wear.
- No known contraindication to dexamethasone acetate.
- Is not receiving mannitol or sorbitol, administered intravenously, or as a component of an irrigation solution or peritoneal dialysis solution, as this may increase blood mannitol or sorbitol concentrations and cause falsely elevated readings of sensor glucose results. Sorbitol is used in some artificial sweeteners, and concentration levels from typical dietary intake do not impact sensor glucose results.
- Is not pregnant or under the age of 18.

\* Blevins T, Bode B, Garg S, Grunberger G, Hirsch I, Jovanovic L, et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring. *Endocrine Practice*, 2010; 16(5): A.

## Pre-Insertion Training Activities for Patient

- Download Eversense App to compatible mobile device (requirements are listed in *User Guide*) and become familiar with functionality.
- Discuss the importance of setting the correct “Unit of Measure” in the Eversense App.
- Go to <https://global.eversenseddiabetes.com> to learn more about the system.

## To pair Smart Transmitter with Compatible Mobile Device

- Confirm the patient has downloaded the Eversense CGM App from the App Store or Google Play store.
- Charge smart transmitter for 15 minutes.
- Pair smart transmitter to mobile device.
- Set system preferences according to healthcare provider recommendations.
- Instruct patients to bring smart transmitter and mobile device to clinic if it was shipped to patient’s home.

## 4. Eversense E3 CGM System Kit

The Eversense E3 CGM System Kit comes in four packages: 1) Sensor Kit, 2) Insertion Tools Kit, 3) Smart Transmitter Kit, and the 4) Adhesive Kit.


**IMPORTANT:** The Sensor Kit and Insertion Tools Kit contain components that are packaged sterile. Both kits are designed for single patient-use only. DO NOT re-use, re-process or re-sterilise the sensor, blunt dissector, or insertion tool.

**Items Not Included:** Other procedure instruments, tools and equipment are not included and must be provided by the clinic.

### 1. Eversense E3 Sensor Kit (Sensor in holder, Implant Card)

The **Sensor** is shipped sterile inside a protective holder for safe handling purposes. You will need to transfer the sensor to the insertion tool before use. The pouch that holds the sensor is not sterile.

The sensor is approximately 3.5 mm x 18.3 mm and is subcutaneously inserted using the insertion tool. The sensor has a silicone ring that contains an anti-inflammatory steroid drug (dexamethasone acetate). Upon exposure to body fluids the dexamethasone acetate is eluted from the ring in the area near the sensor. The dexamethasone acetate minimises inflammatory responses, very similar to some already available medical devices (e.g., pacemaker leads).



**IMPORTANT:** Store the sensor kit refrigerated at the labelled temperature range.

The blank fields on the **Implant Card** (patient name, insertion date, inserting healthcare provider contact information) are completed by clinic staff and provided to the patient. The other side of the card includes important device information. The patient should keep the card in their wallet for the duration of sensor wear. See example at right. For explanation of the Implant Card symbols, see *Technical Specifications*.

|  |  |
|--|--|
| <b>Senseonics</b> . International Implant Card |  |
|  | John Smith (patient name)  |
|  | 30/03/2022 (insertion date)  |
|  | Dr. Jones (health care provider name, address, phone)  |
|  | 10 Downing Street, LONDON, SW1A 2AA  |
|  | + 44 123 456 7890  |
|  | <a href="http://global.eversensediabates.com/safety-info">global.eversensediabates.com/safety-info</a> |
|  |  |

|  |   |
|--|---|
| EN: sensor / NL: sensor / FR: capteur / DE: sensor / NO: sensor<br>IT: sensore / PL: czujnik / ES: sensor / SV: sensor   |   |
| UDI-DE: 00817491023308   |   |
|  | Eversense E3  |
|  | 123456  |
|  | WP01234   |
| LBL-102920-001 Rev A   |   |
|  | (01) 0 0817491 023308<br>(241) FG-4500-50-302<br>(110) WP01234<br>(21) 123456 |
|  |   |
| Senseonics, Inc.<br>20451 Seneca Meadows Parkway,<br>Germantown, MD 20876-7005 USA<br><a href="http://global.eversensediabates.com">global.eversensediabates.com</a> |   |
| © Senseonics, Inc. 02/2022 LBL-0600-01-300 Rev A   |   |

## 2. Eversense E3 Insertion Tools Kit

(Incision Template , Blunt Dissector, Insertion Tool, Tray, and Insertion/Removal Instructions, DMS Pro Instructions)

The **Incision Template** is used to guide and mark the incision area on the skin surface by aligning the marking template to the marked outer edges of the smart transmitter when placed in a comfortable position.

The **Blunt Dissector** is used to create the subcutaneous pocket for insertion of the sensor. This tool has two depth guards to help prevent the pocket from being made too deep in the skin. The depth guards have guide marks to assist in determining the length of the subcutaneous pocket for placing the sensor.

The **Insertion Tool** is used to insert the sensor inside the subcutaneous pocket created with the blunt dissector. It has two guide marks on the cannula to assist in proper placement.

## 3. Eversense E3 Smart Transmitter Kit

(Smart Transmitter, Power Supply, User Guide, Quick Reference Guide, DMS Instructions, Eversense NOW Instructions)


The **Smart Transmitter** is the reusable and rechargeable device worn externally over the sensor. The smart transmitter wirelessly powers the sensor. Use only the **Power Supply** included in this kit to charge the smart transmitter.

The User Guides are designed for the patient to learn about their Eversense E3 CGM System and its optional accessory components.

## 4. Eversense E3 Adhesive Patches Kit

(180 patches)

The **Adhesive Patch** has an adhesive side that attaches to the back of the smart transmitter and a silicone adhesive side that attaches to the skin intended to be changed daily. The healthcare provider gives these to the patient when they leave the office.



## 5. Product Handling

---

The sensor kit, blunt dissector, and insertion tool have been sterilised by the method indicated on the package labels.

Inspect the condition of the sterile package before opening and using the contents.

- DO NOT use the contents if the package is broken or torn, or if contamination is suspected because of a defective sterile package seal.
- DO NOT re-sterilise the sensor or the components by any sterilisation method.
- **DO NOT use the product if the labelled “Use By” date has passed. Sensors should be inserted before the “Use By” date has passed.**

### Handling and Storage

- Handle the sensor and all other components with care, using appropriate aseptic technique.
- DO NOT open any of the sterile packages until ready for use.
- Keep sharp instruments away from the kit components.
- DO NOT use the sensor or any kit component if it has been dropped on a hard surface from a height of more than 30 cm.
- Store the sensor kit refrigerated at the labelled temperature range.
- Dispose of product packaging in accordance with clinic, administrative and/or local government policy.



## 6. Suggested Equipment

---

**Items Not Included:** Other procedure instruments, tools and equipment are not included in the insertion tools kit and must be provided by the clinic. Please see list of suggested equipment below.

***Materials (or equivalent) suggested for sensor insertion/removal:***

- Chlorhexidine OR Betadine solution
- 2-3 Sterile Gauze Pads
- 1 Disposable Sterile Scalpel (e.g., Disposable Sterile Scalpel, #15)
- 1 Sterile Syringe and Needle (for lidocaine injection)
- Steri-Strip Adhesive Skin Closure and/or available sutures (healthcare provider preference)
- 1 sterile scissors (e.g., disposable) to cut steri-strips
- 1 Sterile Towel Drape
- 1 Sterile Drape with aperture approximately 22 in x 25 in
- 2 Tegaderm™ + Pad Film Dressing
- 1 Lidocaine HCL without epinephrine (1-2 mL)
- 1 Surgical skin marker
- 3 Sterile, non-latex surgical gloves, healthcare provider-preferred size
- 1 10 mL sterile saline filled syringe (for insertion only)
- 1 Sterile surgical clamp 10-16 cm

## 7. Insertion Procedure

Before inserting the sensor, confirm that the patient:

- Does not have allergies to the antiseptic and local anaesthetic to be used during insertion.

**Note:** The procedure below assumes a right-handed healthcare provider with the patient facing (left arm insertion) or looking away from (right arm insertion) the healthcare provider. The dimensions indicated in the instructions are approximate to give a conceptual context of the insertion.

### A. Prep the Insertion Area

1. With the subject seated on the procedure table, position the smart transmitter on the patient's arm to select the insertion location for the sensor.

It is recommended to alternate arms for subsequent insertion sites.

Suggested insertion location is approximately at the midway point between the acromion process and the lateral epicondyle.


Things to consider when choosing insertion location:

- It must be comfortable for the user to wear 24/7. Place the smart transmitter on the intended site and confirm that the patient is comfortable with the placement.
- Not too lateral such that patient cannot easily apply an adhesive patch.
- Avoid area with loose skin such as back of arm.
- Avoid areas with scar tissue, tattoo, nevus, or apparent or noticeable blood vessels that could be incised.

2. Once the position for the smart transmitter is selected, mark the corners on the skin.

3. Using the non-sterile incision template, align the template inside the marked lines and mark the skin for the incision using the incision template's slots.

4. Position the patient in a reclined position preferably on their side, with the elbow flexed up to 90 degrees and the palm resting on the chest or abdomen.



## B. Open the Sensor Kit and Insertion Tools Kit

1. Over the prepared sterile field, remove the sensor holder from the Sensor pouch and remove the sterile inner tray with tools from the Insertion Tools Kit and place in the sterile procedure field created for the procedure.

Note that the inner tray of the Sensor Insertion Kit is sterile and can be placed within the sterile procedure field.



2. Remove the insertion tool from the inner tray and remove its red locking tab by sliding it towards the back of the tool.

Ensure the blue slide stays in the forward position.

3. Snap the tool back into its position in the tray.

4. Wet the cannula by filling the preformed well with enough sterile saline (0.9% sterile saline for injection) to completely cover the cannula (approximately 10 mL).

5. Remove the sensor holder from the sensor pouch and place in the sterile field.





### Cautions

- The sensor and sensor holder are sterile in the unopened, undamaged, sterile package. The sensor should not be used if the sterile package has been opened or damaged.
- DO NOT insert a sensor if it has been dropped from a height of 30 cm or more.
- Use only the insertion tools provided in the insertion tools kit to insert the sensor. Other insertion tools may damage the sensor.

## C. Prepare the Sensor



1. Remove the cap from the end of the sensor holder by pressing the ridged portion and pulling the cap.

Discard the cap.




2. Remove the insertion tool from the tray and retract the blue slide.

With the cannula pointed up, align the slot of the sensor holder with the exposed slot of the thumb slide and the triangle on the side of the sensor holder with the triangle on the insertion tool.






3. With the blue slide retracted, slide the sensor holder over the cannula so that the two triangles are touching at the tip and snap into place.



4. Depress the blue thumb slide down to unlock and advance it all the way forward until it stops.



This action secures the sensor inside the cannula. The cannula, not the sensor, is now visible through the slot in the sensor holder.

**DO NOT RETRACT the thumb slide at this step.**




**5. Depress the ridged portion of the sensor holder to remove it from the insertion tool.**

Discard the sensor holder. You should see the tip of the sensor at the end of the insertion tool.



**6. Place the insertion tool back in its original placement in the tray.**

The insertion tool will snap into position in the insertion kit inner tray and the tip of the cannula with the sensor will be positioned in the preformed well in the tray. To ensure proper hydration, fully submerge the cannula tip in the well for a few minutes (approximately 5 minutes).



## D. Clean and Anaesthetise the Insertion Area

1. If not done previously, position the patient in a reclined position, preferably on their side, with the elbow flexed up to 90 degrees and the palm resting on the chest or abdomen.
2. Clean and disinfect the insertion area.  
Apply disinfectant chlorhexidine to marked area. Cover the arm with sterile drape so opening is around incision site.
3. Anaesthetise the insertion area as appropriate.  
Local anaesthesia (approximately 2 mL of Lidocaine) should be injected approximately 5 mm along the planned incision (along AB) and approximately 30 mm perpendicular to the planned incision (along CD) which is the planned track of the blunt dissector tool. (Figure 1).




Figure 1

## E. Make Incision and Subcutaneous Pocket

1. Once the insertion area is sufficiently anaesthetised, make an approximately 5 mm incision at the insertion location such that you will be able to create an appropriately sized subcutaneous pocket approximately 3-5 mm below the skin surface.

Start incision at point B (Figure 1) and go towards point A, until the incision is approximately 5 mm.

2. Remove the blunt dissector from the tray and introduce the blunt dissector at approximately a 45 degree entry angle at the midline between A and B (Figures 1 & 2) so that the tip and tapered portion of the blunt dissector are under the skin, and until the depth guards are touching the skin.




Figure 2



3. With the tips of the depth guards on the skin and the blunt dissector at the subcutaneous space, lower the angle of skin entry to approximately 5-10 degrees (Figure 3) taking care to ensure that the fingers are not under the metal rod or plastic portions of the tool, which would cause a steeper angle.





Figure 3



4. Move the blunt dissector toward the shoulder, while maintaining the metallic and plastic parts of the tool in close contact with the skin to ensure the smallest possible angle of the pocket with respect to the skin (Figure 3).

Continue advancing the tool until the incision between A and B is within the white guide marks on the depth guards (Approximately 25-30 mm) (Figure 4). Completely retract the blunt dissector and set aside.

#### Note:

- Pinching and tenting the skin can aid in forming a small space in the skin for insertion.
- Slight rotation of the blunt dissector along the axis of the tool while advancing may be helpful.
- DO NOT create a pocket more than 3-5 mm below the skin. If the sensor is placed too deep, it may be difficult to communicate with the smart transmitter or to remove later.
- It is important to ensure that the subcutaneous pocket is parallel to and along the same axis as the humerus bone. When you insert the sensor, it should be level in the pocket, which will facilitate communication between the sensor and the smart transmitter.






Figure 4

## F. Sensor Placement and Incision Closure

1. Using approximately a 45 degree entry angle, place the tip of the insertion tool into the incision opening such that the tip of the cannula is beneath the incision.
2. Similar to steps E3 & E4, lower the entry angle to about 5-10 degrees and advance toward the shoulder following the pocket created by the blunt dissector.
3. Advance the tool until the incision line is between the first and second marked lines on the cannula.  
If necessary, re-use the blunt dissector or widen the incision if excessive force is encountered. DO NOT force the insertion tool into the incision site.
4. Pushing down on the back of the thumb slide to unlock it, retract the thumb slide to deploy the sensor into the pocket.  
The slide locks into place when it has reached the end point. DO NOT re-advance the thumb slide.
5. Lightly palpate the insertion area to confirm that the sensor is in place; remove the insertion tool from the incision.
6. Close and dress the incision in the appropriate manner using adhesive skin closure (e.g., Steri-Strip™) or suture and dressing, making sure the two sides of the incision are closed together without tension.



## G. Insertion Tool and Blunt Dissector Disposal

---

Dispose of used insertion tool and blunt dissector in accordance with clinic, administrative and/or local government policy.

## H. Connecting the Eversense E3 CGM System

---

**Note:** Pairing the transmitter and mobile device, and linking the sensor and transmitter may be performed by the patient at home.

**1. Confirm the patient's mobile device has been paired with the Eversense App and has an internet connection.**

**2. Link the sensor to the smart transmitter.**

- a. Place the smart transmitter directly over the bandage.
- b. On the Eversense App, use the Placement Guide screen to confirm there is a signal.
- c. Navigate away from the Placement Guide page once you have confirmed there is a signal.

**Note:** It may take up to 5 minutes to receive the notification for “New Sensor Detected”. DO NOT remove the smart transmitter from over the insertion site until the linking process is complete.

Refer to the *Eversense E3 CGM System User Guide, Linking the Sensor* for additional information.

## 8. Post-Insertion Patient CGM Start-Up

---

Your patients may need assistance in getting started with the Eversense E3 CGM System. Refer to the *User Guide* and *Quick Reference Guide* that is included in the smart transmitter kit for information on getting the smart transmitter and mobile device ready for use.

This includes:

- Charging the smart transmitter.
- Downloading the Eversense App to their mobile device.
- Personalising the patient's glucose settings.
- Pairing (connecting) the smart transmitter and app.
- Linking the smart transmitter with the sensor after the sensor is inserted.

### **Note:**

- All but the linking step can be completed before the sensor is inserted.
- Patients do not need to secure the smart transmitter over the sensor during the first 24 hours after insertion. After the sensor is linked to the smart transmitter, the sensor requires 24 hours to stabilise in the body before glucose values can be calculated by the smart transmitter.
- If the smart transmitter is secured over the sensor within the first 24 hours after insertion, the patient will receive a message indicating a Warm-Up Phase status of the system and will provide the patient with a 24-hour countdown.
- If the smart transmitter is not secured over the sensor and has been turned off to avoid vibrations, patients must remember to turn the smart transmitter back on at the 24th hour. It will take about 5 minutes after the smart transmitter is placed over the sensor for the first calibration prompt to be displayed. After calibration is completed, the smart transmitter should not be removed for 15 minutes.
- Glucose readings will appear on screen after successfully completing the 2nd calibration.

Review the *Eversense E3 User Guide* to help facilitate your patient's understanding of their new Eversense E3 CGM System and determining their personalised glucose settings.

## 9. Sensor Removal Procedure

---

### A. Locate the Sensor

---

1. Using the initial incision point as a guide, palpate and locate the sensor to determine an appropriate incision location. For reference, mark both ends of the sensor, if possible to palpate.

**Note:** If the sensor cannot be located by palpating, the smart transmitter may be used to aid in locating the sensor. To use the smart transmitter to locate the sensor, open the Placement Guide page in the App. Move the smart transmitter around the sensor insertion area until the screen displays the greatest signal strength. Mark the edges of the smart transmitter at this location and use the incision template to determine the proper incision location.

2. Mark the incision point on the skin.

If the site of the original incision is within 3-5 mm of the distal tip of the sensor, removal can be accessed through the same location.

### B. Prep the Removal Area

---

1. Position the patient in a reclined position, preferably on their side, with the elbow flexed up to 90 degrees and the palm resting on the chest or abdomen.

2. Clean and disinfect the insertion area.

Prepare the insertion site and surrounding area, using aseptic technique.

3. Anaesthetise the insertion area as appropriate for the patient similar to step D3 in section 7.

## C. Incision and Pocket Opening

---

1. Push down on the skin over the expected location of the proximal end of the sensor to stabilise it.
2. Create approximately a 5-6 mm incision through the dermis at the location determined in A2 of this section.

## D. Remove the Sensor

---

1. Carefully dissect the subcutaneous tissue until the end of the sensor distal to the incision can be grasped by a small surgical clamp (such as 10-16 cm). Spreading of the tissue through the incision using the small clamp both parallel and perpendicular to the incision may be required to enable visualisation and grasping of the sensor with the small clamp.
2. Put gentle pressure on the proximal end of the sensor through the skin to help stabilise and facilitate grasping the distal end of the sensor. Use a small clamp to grasp the distal end of the sensor and remove it from the pocket. Rotation of the sensor with the clamp may aid in freeing the sensor from any attached tissue.
3. If the sensor is encapsulated, further dissection may be necessary to grasp and remove the sensor.

## E. Close and Dress the Incision

---

1. Close and dress the incision in the appropriate manner using adhesive skin closure (e.g., Steri-Strip™) or suture, making sure the two sides of the incision are closed together without tension.

## F. Sensor Disposal

---

1. Dispose of sensor according to your area's local regulations.

# 10. Potential Complications

---

The insertion and removal of the Eversense E3 Sensor is a minor procedure and requires aseptic technique to minimise the possibility of infection. Please review this document for complete training.

## A. During Insertion Process

---

### 1. Unable to insert blunt dissector through incision

#### *a. Incision may be too small*

Increase incision size by 2-3 mm and re-insert the blunt dissector.

#### *b. Refer to tips for proper insertion technique in this document*

- Pinching or tenting the skin can aid in forming a small pocket for the insertion.
- Slight rotation of the blunt dissector along the axis of the tool may be helpful.
- DO NOT create a pocket more than 3-5 mm below surface of skin.

### 2. Unable to advance the insertion tool into the subcutaneous pocket

#### *a. Ensure the insertion tool is below the incision when advancing into subcutaneous pocket*

#### *b. Incision size may be too small*

Increase incision size by 2-3 mm with scalpel and re-insert the insertion tool.

### 3. Unable to locate the subcutaneous pocket with the insertion tool when inserting the sensor

Re-insert the blunt dissector into incision to ensure subcutaneous pocket is adequate.

### 4. Subject experiences pain during the procedure

Administer additional local anaesthetic as required.

### 5. Excessive bleeding after incision is made

Apply pressure until bleeding subsides.

## B. During Removal Process

---

### 1. Unable to palpate/locate the sensor

Use the Placement Guide on the app and the smart transmitter to find the sensor. Once the location of the sensor is made with the Placement Guide, mark the position of the smart transmitter on the skin and use the incision template to mark the point of incision. In some cases, an ultrasound may be required to locate the proper point of the incision.

### 2. Excessive bleeding after the sensor is removed

Apply pressure and, if necessary, use sutures to close incision in place of Steri-Strips™.

### 3. Subject experiences pain during the procedure

Administer additional local anaesthetic as required.

### 4. Tissue encapsulation prevents sensor from moving

Dissect encapsulation by spreading the tissue using the small clamp/other desired instrument as required. Gently rotate the small clamp with the secured sensor to release any small fibrous tissue encapsulation.



## II. Device Performance

---

*This section lists Device Performance Characteristics.*

### **Clinical Study Performance**

The safety and effectiveness of the Eversense E3 CGM System has been evaluated in the PROMISE clinical study conducted in the U.S. The data included in this Device Performance section is based on the data collected during the PROMISE study with new algorithm (SW604) and minor design modification in the Sensor (E3 Sensor). Accuracy assessments were made at various points during the study and subjects were asked to report any adverse events throughout the study. The Safety section reflects all subjects (n=181) from the study.

#### **PROMISE Study**

The PROMISE study was a multi-site, prospective, non-randomised pivotal clinical study. One hundred and eighty-one (181) adults (18 years and older) with type 1 or type 2 diabetes participated in the study across 8 sites in the U.S. Ninety-six (96) subjects had two sensors inserted, one in each arm. Forty-three (43) of the secondary sensors were SBA sensors. Participants interacted with the system to calibrate and address notifications not related to glucose data. All diabetes care decisions were based on blood glucose values and clinical standard of care. Accuracy was measured during day-long clinic visits. These visits occurred on Days 1, 7 or 14, 22, 30, 60, 90, 120, 150, and 180. At each visit, sensor accuracy was evaluated relative to a standard laboratory analyser known as the YSI. Glucose readings were compared at the same moment in time between the reference analyser and the continuous device. A safety follow-up visit occurred ten days after the sensor was removed.

Table 1 – Accuracy to YSI in PROMISE\*

| Total Number of Paired<br>CGM and YSI Values | Percent of CGM System Readings Within |                                |                                |                                | MARD |
|--|---------------------------------------|--------------------------------|--------------------------------|--------------------------------|------|
|  | Percent 15/15%<br>of Reference        | Percent 20/20%<br>of Reference | Percent 30/30%<br>of Reference | Percent 40/40%<br>of Reference |      |
| 12,034                                       | 87.3                                  | 93.9                           | 98.6                           | 99.6                           | 8.5% |

\*Glucose values between 40 and 400 mg/dL.

## Eversense E3 Accuracy to YSI in PROMISE Study

Accuracy was measured by comparing the Eversense E3 sensor glucose values to YSI blood glucose values. For blood glucose values less than or equal to 80 mg/dL, the mean absolute difference between the two results was calculated. For values greater than 80 mg/dL, the mean absolute relative difference was calculated.

**Table 2 – Accuracy to YSI in PROMISE Study**

| YSI Glucose Ranges (mg/dL) | Number of Paired CGM-YSI | Mean Absolute Relative Difference (%) |
|----------------------------|--------------------------|---------------------------------------|
| Overall                    | 12,034                   | 8.5                                   |
| < 40*                      | 0                        | --                                    |
| 40 - 60*                   | 592                      | 7.5                                   |
| 61 - 80*                   | 1,221                    | 7.7                                   |
| 81 - 180                   | 5,067                    | 8.6                                   |
| 181 - 300                  | 3,300                    | 7.4                                   |
| 301 - 350                  | 1,457                    | 6.9                                   |
| 351 - 400                  | 375                      | 6.4                                   |
| > 400                      | 25                       | 9.5                                   |

\*For YSI  $\leq$  80 mg/dL, the differences in mg/dL are included instead of percent difference (%).

Performance was also measured by calculating the percentage of sensor glucose readings within 15 mg/dL or 15% of the YSI reference. These tables show the percent agreement at multiple levels, at different glucose ranges, and at different days during the sensor wear. Results in the glucose ranges of 80 mg/dL or less reflect the percentage of values within mg/dL, and results in the glucose ranges over 80 mg/dL reflect the percentage within reference. As an example, glucose values between 40 and 60 mg/dL were within 15 mg/dL of the reference value 91.6% of the time.

**Table 3 – Eversense E3 Percentage of Readings in Agreement Overall in the PROMISE Study**

| CGM System Glucose Range (mg/dL) | Paired CGM and YSI Reference | Percent of CGM System Readings Within |                             |                             |                             |                               |
|----------------------------------|------------------------------|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|
|                                  |                              | Percent 15/15% of Reference           | Percent 20/20% of Reference | Percent 30/30% of Reference | Percent 40/40% of Reference | Percent > 40/40% of Reference |
| Overall                          | 12,034                       | 87.3                                  | 93.9                        | 98.6                        | 99.6                        | 0.4                           |
| 40 - 60                          | 574                          | 91.6                                  | 96.5                        | 98.6                        | 99.3                        | 0.7                           |
| 61 - 80                          | 1,178                        | 89.7                                  | 93.8                        | 98.9                        | 99.8                        | 0.2                           |
| 81 - 180                         | 5,078                        | 85.1                                  | 93.2                        | 98.5                        | 99.6                        | 0.4                           |
| 181 - 300                        | 3,493                        | 87.0                                  | 93.7                        | 98.4                        | 99.6                        | 0.4                           |
| 301 - 350                        | 1,191                        | 93.3                                  | 96.8                        | 99.2                        | 99.6                        | 0.4                           |
| 351 - 400                        | 520                          | 87.3                                  | 93.8                        | 98.7                        | 99.6                        | 0.4                           |

**Table 4 – Eversense E3 System Accuracy by Day**

| Day     | Mean Absolute Relative Difference (%) | Percent of CGM System Readings Within |                             |                             |                             |                               |
|---------|---------------------------------------|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|
|         |                                       | Percent 15/15% of Reference           | Percent 20/20% of Reference | Percent 30/30% of Reference | Percent 40/40% of Reference | Percent > 40/40% of Reference |
| Day 1   | 11.2                                  | 78.6                                  | 87.4                        | 96.5                        | 99.3                        | 0.7                           |
| Day 7   | 10.0                                  | 81.9                                  | 88.0                        | 94.7                        | 98.5                        | 1.5                           |
| Day 14  | 7.4                                   | 87.4                                  | 95.0                        | 99.0                        | 100.0                       | 0.0                           |
| Day 22  | 8.4                                   | 88.9                                  | 95.7                        | 99.2                        | 99.9                        | 0.1                           |
| Day 30  | 8.2                                   | 85.8                                  | 93.4                        | 98.2                        | 99.3                        | 0.7                           |
| Day 60  | 8.6                                   | 87.9                                  | 94.2                        | 98.6                        | 99.8                        | 0.2                           |
| Day 90  | 7.0                                   | 93.1                                  | 97.1                        | 99.8                        | 99.9                        | 0.1                           |
| Day 120 | 8.4                                   | 89.2                                  | 96.1                        | 99.6                        | 99.9                        | 0.1                           |
| Day 150 | 8.8                                   | 84.0                                  | 91.9                        | 99.5                        | 99.9                        | 0.1                           |
| Day 180 | 7.4                                   | 93.1                                  | 98.0                        | 99.3                        | 99.7                        | 0.3                           |

**Eversense E3 Alert Performance**

The tables in this section show an alert performance assessment. The Confirmed Event Detection Rate shows the percentage of time the Eversense E3 CGM System confirmed the reference value by presenting an alert within a 15 minute window of a reference value beyond the alert setting threshold. The Missed Detection Rate shows the percentage of time the Eversense E3 CGM System did not present an alert within a 15 minute window of a reference value beyond the alert setting threshold. The True Alert Rate shows the percentage of time the alert from the CGM system was confirmed by a reference value within a 15 minute window of the alert being presented. The False Alert Rate shows the percentage of time the alert from the CGM system was not confirmed by a reference value within a 15 minute window of the alert being presented.

The table below shows an assessment of the ability of the Eversense E3 CGM System to detect high and low glucose levels, and assess true positive alerts vs false positive alerts. These are shown as a percentage of alerts provided compared to the YSI reference values at various thresholds.

**Table 5 – Eversense E3 High and Low Glucose Alert Performance (Threshold Only) in the PROMISE Study**

| Alert Setting (mg/dL) |     | Confirmed Event Detection Rate | Missed Detection Rate | True Alert Rate | False Alert Rate |
|-----------------------|-----|--------------------------------|-----------------------|-----------------|------------------|
| Low Alert             | 60  | 76%                            | 24%                   | 82%             | 18%              |
|                       | 70  | 89%                            | 11%                   | 90%             | 10%              |
|                       | 80  | 93%                            | 7%                    | 92%             | 8%               |
|                       | 90  | 96%                            | 4%                    | 93%             | 7%               |
| High Alert            | 120 | 99%                            | 1%                    | 97%             | 3%               |
|                       | 140 | 99%                            | 1%                    | 96%             | 4%               |
|                       | 180 | 98%                            | 2%                    | 95%             | 5%               |
|                       | 200 | 97%                            | 3%                    | 95%             | 5%               |
|                       | 220 | 97%                            | 3%                    | 95%             | 5%               |
|                       | 240 | 97%                            | 3%                    | 94%             | 6%               |
|                       | 300 | 88%                            | 12%                   | 90%             | 10%              |

The table below shows an assessment of the ability of the Eversense E3 CGM System to detect high, low, and predictive high and low alerts, and assess true positive alerts vs false positive alerts. These are shown as a percentage of alerts provided compared to the YSI reference values at various thresholds.

**Table 6 – Eversense E3 High, Low, and Predictive Alert Performance (Threshold and Predictive) in the PROMISE Study**

| Alert Setting (mg/dL) |     | Confirmed Event Detection Rate | Missed Detection Rate | True Alert Rate | False Alert Rate |
|-----------------------|-----|--------------------------------|-----------------------|-----------------|------------------|
| Low Alert             | 60  | 90%                            | 10%                   | 73%             | 27%              |
|                       | 70  | 94%                            | 6%                    | 84%             | 16%              |
|                       | 80  | 97%                            | 3%                    | 87%             | 13%              |
|                       | 90  | 98%                            | 2%                    | 89%             | 11%              |
| High Alert            | 120 | 99%                            | 1%                    | 96%             | 4%               |
|                       | 140 | 99%                            | 1%                    | 95%             | 5%               |
|                       | 180 | 99%                            | 1%                    | 93%             | 7%               |
|                       | 200 | 99%                            | 1%                    | 93%             | 7%               |
|                       | 220 | 98%                            | 2%                    | 92%             | 8%               |
|                       | 240 | 98%                            | 2%                    | 91%             | 9%               |
|                       | 300 | 92%                            | 8%                    | 87%             | 13%              |



### Eversense E3 Rate of Change Trend Agreement

The shaded area in the table below shows agreement between the Eversense E3 glucose trends and the YSI reference trends while glucose is trending at different rates (mg/dL per minute). As an example, when glucose is trending at a rate of between -1 and 1 mg/dL/minute, Eversense E3 glucose trends are in agreement with the reference trends 90% of the time.

**Table 7 – Eversense E3 Rate of Change Trend Agreement in the PROMISE Study**

| CGM Trend (mg/dL/min) | Reference Rate of Change (mg/dL/min) Percent of Matched Pairs in Each Reference Trend Range for Each CGM ROC Range |          |         |        |     |        |
|-----------------------|--|----------|---------|--------|-----|--------|
|                       | < -2   | [-2, -1) | [-1, 1] | (1, 2] | > 2 | Total  |
| < -2                  | 24%  | 35%      | 41%     | 0%     | 0%  | 163    |
| [-2, -1)              | 4%   | 36%      | 59%     | 0%     | 0%  | 824    |
| [-1, 1]               | 0%   | 4%       | 90%     | 5%     | 1%  | 8,716  |
| (1, 2]                | 0%   | 1%       | 46%     | 42%    | 11% | 896    |
| > 2                   | 0%   | 0%       | 24%     | 40%    | 35% | 336    |
|                       |  |          |         |        |     | 10,935 |

### Eversense E3 Concurrence with YSI Values

The shaded area in the tables below show what percentage of YSI reference values were in the same range as the sensor glucose values. As an example, when sensor glucose is between 81 and 120 mg/dL, YSI reference values are in the same range 76% of the time.

**Table 8 – Concurrence with YSI Range All Days in the PROMISE Study**

| CGM<br>(mg/dL) | Number of<br>Paired CGM-YSI | Percent of Matched Pairs in Each YSI Glucose Range for Each CGM Glucose Range YSI (mg/dL) |         |         |          |           |           |           |           |           |           |       |
|----------------|-----------------------------|---|---------|---------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-------|
|                |                             | < 40  | 40 - 60 | 61 - 80 | 81 - 120 | 121 - 160 | 161 - 200 | 201 - 250 | 251 - 300 | 301 - 350 | 351 - 400 | > 400 |
| 40 - 60        | 574                         | 0%  | 62%     | 36%     | 1%       | 0%        | 0%        | 0%        | 0%        | 0%        | 0%        | 0%    |
| 61 - 80        | 1,178                       | 0%  | 19%     | 66%     | 15%      | 0%        | 0%        | 0%        | 0%        | 0%        | 0%        | 0%    |
| 81 - 120       | 2,066                       | 0%  | 0%      | 11%     | 76%      | 12%       | 0%        | 0%        | 0%        | 0%        | 0%        | 0%    |
| 121 - 160      | 2,067                       | 0%  | 0%      | 0%      | 14%      | 71%       | 14%       | 0%        | 0%        | 0%        | 0%        | 0%    |
| 161 - 200      | 1,648                       | 0%  | 0%      | 0%      | 0%       | 21%       | 66%       | 13%       | 0%        | 0%        | 0%        | 0%    |
| 201 - 250      | 1,437                       | 0%  | 0%      | 0%      | 0%       | 1%        | 15%       | 68%       | 15%       | 1%        | 0%        | 0%    |
| 251 - 300      | 1,353                       | 0%  | 0%      | 0%      | 0%       | 0%        | 1%        | 17%       | 56%       | 25%       | 1%        | 0%    |
| 301 - 350      | 1,191                       | 0%  | 0%      | 0%      | 0%       | 0%        | 0%        | 1%        | 17%       | 70%       | 12%       | 0%    |
| 351 - 400      | 520                         | 0%  | 0%      | 0%      | 0%       | 0%        | 0%        | 0%        | 3%        | 51%       | 42%       | 5%    |
| > 400          | 155                         | 0%  | 0%      | 0%      | 0%       | 0%        | 0%        | 0%        | 1%        | 21%       | 52%       | 26%   |

**Table 9 – Concurrence with YSI Range Day 1 in the PROMISE Study**

| CGM (mg/dL) | Number of Paired CGM-YSI | Percent of Matched Pairs in Each YSI Glucose Range for Each CGM Glucose Range YSI (mg/dL) |         |         |          |           |           |           |           |           |           |       |
|-------------|--------------------------|---|---------|---------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-------|
|             |                          | < 40  | 40 - 60 | 61 - 80 | 81 - 120 | 121 - 160 | 161 - 200 | 201 - 250 | 251 - 300 | 301 - 350 | 351 - 400 | > 400 |
| 40 - 60     | 120                      | 0%  | 51%     | 45%     | 3%       | 1%        | 0%        | 0%        | 0%        | 0%        | 0%        | 0%    |
| 61 - 80     | 146                      | 0%  | 10%     | 54%     | 36%      | 0%        | 0%        | 0%        | 0%        | 0%        | 0%        | 0%    |
| 81 - 120    | 271                      | 0%  | 0%      | 5%      | 70%      | 25%       | 0%        | 0%        | 0%        | 0%        | 0%        | 0%    |
| 121 - 160   | 202                      | 0%  | 0%      | 0%      | 14%      | 62%       | 21%       | 3%        | 0%        | 0%        | 0%        | 0%    |
| 161 - 200   | 124                      | 0%  | 0%      | 0%      | 0%       | 33%       | 51%       | 16%       | 0%        | 0%        | 0%        | 0%    |
| 201 - 250   | 75                       | 0%  | 0%      | 0%      | 0%       | 4%        | 19%       | 51%       | 27%       | 0%        | 0%        | 0%    |
| 251 - 300   | 121                      | 0%  | 0%      | 0%      | 0%       | 0%        | 1%        | 24%       | 57%       | 18%       | 0%        | 0%    |
| 301 - 350   | 86                       | 0%  | 0%      | 0%      | 0%       | 0%        | 0%        | 3%        | 33%       | 64%       | 0%        | 0%    |
| 351 - 400   | 58                       | 0%  | 0%      | 0%      | 0%       | 0%        | 0%        | 0%        | 7%        | 84%       | 9%        | 0%    |
| > 400       | 25                       | 0%  | 0%      | 0%      | 0%       | 0%        | 0%        | 0%        | 4%        | 48%       | 48%       | 0%    |

## Calibration Stability Agreement

The table below compares the percentage of sensor glucose values to the YSI reference at various time points after a calibration entry. As an example, in the table below, 89.7% of the Eversense E3 values were within 15 mg/dL (for reference readings of 80 mg/dL or less), and within 15% (for reference readings over 80 mg/dL) of the reference value 8 to 10 hours after a calibration entry.

**Table 10 – Eversense E3 Calibration Stability Agreement in the PROMISE Study**

| Time from Calibration | Number of Paired CGM-YSI | Percent of CGM System Readings Within |                             |                             |                             |                               |
|-----------------------|--------------------------|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|
|                       |                          | Percent 15/15% of Reference           | Percent 20/20% of Reference | Percent 30/30% of Reference | Percent 40/40% of Reference | Percent > 40/40% of Reference |
| (0, 2) Hours          | 2,638                    | 88.8                                  | 94.1                        | 98.7                        | 99.9                        | 0.1                           |
| [2, 4) Hours          | 1,905                    | 87.2                                  | 94.4                        | 98.5                        | 99.5                        | 0.5                           |
| [4, 6) Hours          | 1,404                    | 85.3                                  | 93.3                        | 98.1                        | 99.3                        | 0.7                           |
| [6, 8) Hours          | 1,043                    | 83.0                                  | 91.5                        | 97.7                        | 99.6                        | 0.4                           |
| [8, 10) Hours         | 1,041                    | 89.7                                  | 93.9                        | 98.8                        | 99.6                        | 0.4                           |
| [10, 12) Hours        | 1,091                    | 87.8                                  | 94.1                        | 97.7                        | 99.5                        | 0.5                           |
| [12, 14) Hours        | 590                      | 85.8                                  | 93.4                        | 99.0                        | 99.3                        | 0.7                           |
| [14, 16) Hours        | 440                      | 82.7                                  | 91.8                        | 100.0                       | 100.0                       | 0.0                           |
| [16, 18) Hours        | 379                      | 87.6                                  | 93.9                        | 99.5                        | 100.0                       | 0.0                           |
| [18, 20) Hours        | 370                      | 90.0                                  | 97.0                        | 98.4                        | 99.7                        | 0.3                           |

**Table 10 – Eversense E3 Calibration Stability Agreement in the PROMISE Study** (continued)

| Time from Calibration | Number of Paired CGM-YSI | Percent of CGM System Readings Within |                             |                             |                             |                               |
|-----------------------|--------------------------|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|
|                       |                          | Percent 15/15% of Reference           | Percent 20/20% of Reference | Percent 30/30% of Reference | Percent 40/40% of Reference | Percent > 40/40% of Reference |
| [20, 22) Hours        | 436                      | 88.3                                  | 94.5                        | 99.5                        | 99.8                        | 0.2                           |
| [22, 24) Hours        | 522                      | 89.7                                  | 96.2                        | 99.4                        | 99.8                        | 0.2                           |
| [24, 26) Hours        | 168                      | 93.5                                  | 98.2                        | 99.4                        | 100.0                       | 0.0                           |
| [26, 28) Hours        | 7                        | 100.0                                 | 100.0                       | 100.0                       | 100.0                       | 0.0                           |

**Sensor Life**

Sensor life measured the percentage of sensors being able to function through the intended 180 day duration. In the PROMISE study, 90% of sensors were estimated to function through the 180 day period.

**Percentage of Sensors that lasted 60, 120 and 180 days**

| Days | Sensor Life | Average # of Days |
|------|-------------|-------------------|
| 60   | 98%         | 175               |
| 120  | 98%         |                   |
| 180  | 90%         |                   |

## Safety

The PROMISE study lasted for 180 days, and the number of related adverse events was recorded. The Eversense E3 CGM System was well tolerated in the study. During the study's 31,373 sensor wear days, there were no unanticipated adverse events. Fifty-nine adverse events were reported in 37 participants. None of the adverse events resulted in hospitalisation.

**Table 11 – Adverse Events (All Subjects, n = 181)**

| Event Type  | Number of Events | Number of Subjects (% of Subjects) |
|---|------------------|------------------------------------|
|   | 59               | 37 (20.4)                          |
| Skin irritation, adhesive patch location or insertion site (including erythema, pruritus, rash, contact dermatitis, seroma) | 16               | 11 (6.1)                           |
| Skin atrophy  | 4                | 4 (2.2)                            |
| Hypopigmentation  | 4                | 3 (1.7)                            |
| Infection (procedure related)   | 2                | 2 (1.1)                            |
| Infection (not procedure related)   | 1                | 1 (0.6)                            |
| Bruising  | 19               | 11 (6.1)                           |
| Bleeding  | 3                | 3 (1.7)                            |
| Pain  | 7                | 6 (3.3)                            |
| Arm Numbness  | 1                | 1 (0.6)                            |
| Tremor  | 1                | 1 (0.6)                            |
| Adhesive Skin Closure Strips did not hold   | 1                | 1 (0.6)                            |

## 12. Technical Specifications

| Sensor        | Description  |
|---------------|--|
| Length        | 18.3 mm  |
| Diameter      | 3.5 mm   |
| Materials     | Homopolymer polymethylmethacrylate (PMMA) - 86 mg, Hydroxyethylmethacrylate (HEMA) based Hydrogel containing glucose indicator - 2.0 mg, Platinum - 0.012 mg, Silicone - 4.1 mg, Dexamethasone Acetate - 1.7 mg, epoxy 301-2 - 0.62 mg |
| Storage Temp  | Between 2°C (36°F) and 8°C (46°F)  |
| Sterilisation | Sterile by Ethylene Oxide  |

| Blunt Dissector | Description  |
|-----------------|--|
| Materials       | Acrylonitrile butadiene styrene (ABS), Stainless Steel |
| Storage Temp    | Between 10°C (50°F) and 30°C (86°F)                    |
| Sterilisation   | Sterile by Ethylene Oxide                              |

| Insertion Tool | Description  |
|----------------|--|
| Materials      | Acrylonitrile butadiene styrene (ABS) and Polytetrafluoroethylene (PTFE); Cyanoacrylate adhesive and Stainless Steel |
| Storage Temp   | Between 10°C (50°F) and 30°C (86°F)  |
| Sterilisation  | Sterile by Ethylene Oxide  |

| Sensor Holder | Description  |
|---------------|--|
| Materials     | Acrylonitrile butadiene styrene (ABS) and Polytetrafluoroethylene (PTFE) |








| Power Supply and Charger | Description                                 |
|--------------------------|---|
| Class                    | II  |
| Input                    | AC Input, 100-240 Vac, 50/60 Hz, 0.3-0.15 A |
| DC Output                | 5V DC, 1A (5.0 watts)                       |
| Moisture Protection      | IP22  |









| USB Cable* for Charging and Downloading | Description          |
|---|----------------------|
| Input/Output                            | 5V DC, 1A            |
| Type                                    | USB-A to USB micro-B |
| Length                                  | 36 inches (91 cm)    |






\*If misused, the USB cable can pose a strangulation risk. The USB cable can be connected to the power supply/charger and charged using an AC power outlet. To isolate the system, unplug the charger/power supply from the outlet. If you charge the smart transmitter using a USB port on your personal computer, ensure the personal computer complies with the IEC 60950-1 (or equivalent) safety standard.










## Symbols on Packaging and Device








| Symbol  | Explanation   |
|---|---|
|  | Consult accompanying documents                      |
|  | Caution, consult accompanying documents             |
|  | Use by  |
|  | Manufacturer  |
|  | Date of manufacture                                 |
|  | Storage temperature limits                          |
|  | Authorised representative in the European Community |





| Symbol  | Explanation  |
|---|--|
|  | Marking certifies that the device meets Medical Device Regulation 2017/745 |
|  | Lot number   |
|  | Part number  |
|  | Serial number  |
|  | Type BF Applied Part   |
|  | Non-ionising electromagnetic radiation                                     |
|  | Not made with natural rubber latex   |
|  | Universal Serial Bus (USB)   |

| Symbol  | Explanation  |
|---|--|
|  | FCC ID is assigned to all devices subject to certification   |
|  | Sterilised using Ethylene Oxide  |
|  | Single sterile barrier: Sterilised using Ethylene Oxide  |
|  | Magnetic Resonance Imaging (MRI) procedures are contraindicated for the smart transmitter  |
|  | MR Conditional. An item with demonstrated safety in the MR environment within defined conditions including conditions for the static magnetic field, the time-varying gradient magnetic fields and the radio frequency fields. Please refer to the <i>MRI Safety Information</i> section for complete information. |

## Symbols on Packaging and Device (continued)

| Symbol  | Explanation   |
|---|---|
|  | European Union WEEE Directive 2012/19/EU  |
|  | Single use only   |
|  | DO NOT re-sterilise   |
|  | DO NOT use if package is damaged  |
|  | Non-sterile   |
|  | U.S. (Federal) law restricts the sale of the Eversense E3 CGM System to sale by or on the order of a doctor |
|  | Follow instructions for use   |

| Symbol  | Explanation  |
|---|--|
|  | Medical Device (Note: On the implant card, this indicates the device name) |
|  | Unique Device Identifier   |
|  | Date of insertion  |
|  | Implanting healthcare centre or doctor                                     |
|  | Patient identification (name)  |
|  | Patient information website  |
|  | Importer   |

| Symbol  | Explanation                    |
|---|--------------------------------|
|  | Single patient multiple use    |
|  | Contains a medicinal substance |
|  | Recycling information          |
|  | Distributor                    |



Basic UDI/DI:

- Eversense E3 Sensor Kit: 081749102FG4500TF
- Eversense E3 Insertion Tool Kit: 081749102FG8501UD

Call 04-6175390 for Customer Support.

Distributed by:

DYN Diagnostics Ltd.  
7 Ha'eshel St. P.O. Box 3063  
Caesarea Industrial Park 3079504, Israel  
Phone: 04-6175390  
Email: [patient.care@dyn.co.il](mailto:patient.care@dyn.co.il)



**Senseonics, Inc.**

20451 Seneca Meadows Parkway  
Germantown, MD 20876-7005 USA

[global.eversenseddiabetes.com](http://global.eversenseddiabetes.com)

Patents: [www.senseonics.com/products/patents](http://www.senseonics.com/products/patents)



**Emergo Europe**  
Prinsessegracht 20  
2514 AP, The Hague  
The Netherlands



(241) LBL-4204-31-201\_REV\_D

Eversense E3, Eversense E3 Continuous Glucose Monitoring, Eversense E3 CGM, Eversense E3 Sensor, Eversense E3 Smart Transmitter, Eversense App and the Eversense E3 logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective holders.

© Senseonics, Inc. 2023 PN: LBL-4204-31-201 Rev D 03/2023